{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:41:24Z","timestamp":1780098084851,"version":"3.54.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cld.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T19:16:39Z","timestamp":1711480599000},"page":"331-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Future Therapies of Hepatic Encephalopathy"],"prefix":"10.1016","volume":"28","author":[{"given":"Adam P.","family":"Buckholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cld.2024.02.002_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40265-018-1019-y","article-title":"Impact of hepatic encephalopathy in cirrhosis on quality-of-life issues","volume":"79","author":"Montagnese","year":"2019","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.cld.2024.02.002_bib2","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3748\/wjg.v26.i18.2221","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care","volume":"26","author":"Bohra","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40265-018-1018-z","article-title":"Hepatic encephalopathy: definition, clinical grading and diagnostic principles","volume":"79","author":"Weissenborn","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.cld.2024.02.002_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1440-1746.2001.02487.x","article-title":"Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis","volume":"16","author":"Das","year":"2001","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2024.02.002_bib5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/lt.24153","article-title":"The impact of pretransplant hepatic encephalopathy on survival following liver transplantation","volume":"21","author":"Wong","year":"2015","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.cld.2024.02.002_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11011-005-7205-0","article-title":"Ammonia and hepatic encephalopathy: the more things change, the more they remain the same","volume":"20","author":"Shawcross","year":"2005","journal-title":"Metab Brain Dis"},{"issue":"1\u20132","key":"10.1016\/j.cld.2024.02.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02833598","article-title":"Ammonia: key factor in the pathogenesis of hepatic encephalopathy","volume":"6","author":"Butterworth","year":"1987","journal-title":"Neurochem Pathol"},{"issue":"4","key":"10.1016\/j.cld.2024.02.002_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1020688925901","article-title":"Astroglial dysfunction in hepatic encephalopathy","volume":"13","author":"Norenberg","year":"1998","journal-title":"Metab Brain Dis"},{"issue":"3","key":"10.1016\/j.cld.2024.02.002_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/glia.20003","article-title":"Glutamine-induced free radical production in cultured astrocytes","volume":"46","author":"Jayakumar","year":"2004","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.cld.2024.02.002_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0301-0082(02)00019-9","article-title":"Neurobiology of ammonia","volume":"67","author":"Felipo","year":"2002","journal-title":"Prog Neurobiol"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0301-0082(92)90008-3","article-title":"Effect of ammonium ions on synaptic transmission in the mammalian central nervous system","volume":"39","author":"Szerb","year":"1992","journal-title":"Prog Neurobiol"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jceh.2018.04.007","article-title":"Hepatic encephalopathy and sarcopenia: two faces of the same metabolic alteration","volume":"9","author":"Lattanzi","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"7443","key":"10.1016\/j.cld.2024.02.002_bib13","first-page":"890","article-title":"Treatment of chronic portal-systemic encephalopathy with lactulose","volume":"1","author":"Bircher","year":"1966","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-023-07935-z","article-title":"Barriers to lactulose adherence in patients with cirrhosis and hepatic encephalopathy","volume":"68","author":"Chow","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","article-title":"Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections","volume":"3","author":"Gerard","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cld.2024.02.002_bib16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3389\/fcimb.2021.761192","article-title":"Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome","volume":"11","author":"Yu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","article-title":"Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial","volume":"76","author":"Patel","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2024.02.002_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3748\/wjg.v18.i8.767","article-title":"Rifaximin vs conventional oral therapy for hepatic encephalopathy: a meta-analysis","volume":"18","author":"Eltawil","year":"2012","journal-title":"World J Gastroenterol : WJG"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib19","first-page":"542","article-title":"Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy","volume":"39","author":"Strauss","year":"1992","journal-title":"Hepato-Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib20","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/hep.26314","article-title":"Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy","volume":"57","author":"Laleman","year":"2013","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2024.02.002_bib21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2005.089482","article-title":"Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy","volume":"55","author":"Kochar","year":"2006","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2024.02.002_bib22","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.26185","article-title":"Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial","volume":"57","author":"Ba\u00f1ares","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/jgh.13666","article-title":"Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy","volume":"32","author":"Sharma","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib24","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","article-title":"Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study","volume":"59","author":"Sim\u00f3n-Talero","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2024.02.002_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.dld.2021.04.030","article-title":"Efficacy and safety of albumin infusion for overt hepatic encephalopathy: a systematic review and meta-analysis","volume":"53","author":"Teh","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2022.09.009","article-title":"A\u00a0double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study","volume":"78","author":"Fagan","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2024.02.002_bib27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.metabol.2012.07.007","article-title":"Ammonium metabolism in humans","volume":"61","author":"Adeva","year":"2012","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/hep.29410","article-title":"L-ornithine L-aspartate in bouts of overt hepatic encephalopathy","volume":"67","author":"Sidhu","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2024.02.002_bib29","first-page":"CD012410","article-title":"L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"2018","author":"Goh","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/nu10010088","article-title":"Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease","volume":"10","author":"Himoto","year":"2018","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.cld.2024.02.002_bib31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/BF01307509","article-title":"Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial","volume":"36","author":"Riggio","year":"1991","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s12937-019-0461-3","article-title":"Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis","volume":"18","author":"Shen","year":"2019","journal-title":"Nutr J"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cphy.c120010","article-title":"Renal ammonia metabolism and transport","volume":"3","author":"Weiner","year":"2013","journal-title":"Compr Physiol"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib34","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1172\/JCI116903","article-title":"Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat","volume":"92","author":"Dejong","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00005792-196645060-00011","article-title":"Relation of potassium depletion to renal ammonium metabolism and hepatic coma","volume":"45","author":"Gabuzda","year":"1966","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.cld.2024.02.002_bib36","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/MCG.0b013e318299c789","article-title":"Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study","volume":"47","author":"Ventura-Cots","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/1756283X16658252","article-title":"Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients","volume":"9","author":"Ventura-Cots","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2024.02.002_bib38","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.cgh.2020.10.019","article-title":"Efficacy and safety of ornithine phenylacetate for treating overt hepatic encephalopathy in a randomized trial","volume":"19","author":"Rahimi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2024.02.002_bib39","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1097\/PG9.0000000000000210","article-title":"Secondary ammonia scavenge with glycerol phenylbutyrate improves hyperammonemia following portosystemic shunting","volume":"3","author":"Kortbeek","year":"2022","journal-title":"JPGN Rep"},{"issue":"3","key":"10.1016\/j.cld.2024.02.002_bib40","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep.26611","article-title":"Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy","volume":"59","author":"Rockey","year":"2014","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2024.02.002_bib41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jhbp.947","article-title":"Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: a randomized double-blind controlled trial","volume":"28","author":"Glal","year":"2021","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"issue":"9","key":"10.1016\/j.cld.2024.02.002_bib42","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.cld.2024.02.002_bib43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cgh.2022.05.042","article-title":"Dosing of rifaximin soluble solid dispersion tablets in adults with cirrhosis: 2 randomized, placebo-controlled trials","volume":"21","author":"Bajaj","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7516","key":"10.1016\/j.cld.2024.02.002_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cld.2024.02.002_bib45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/diseases7040058","article-title":"Role of gut dysbiosis in liver diseases: what have we learned so far?","volume":"7","author":"Fukui","year":"2019","journal-title":"Diseases"},{"issue":"NOV","key":"10.1016\/j.cld.2024.02.002_bib46","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3389\/fmicb.2017.02222","article-title":"Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients","volume":"8","author":"Wang","year":"2017","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.cld.2024.02.002_bib47","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/hep.20194","article-title":"Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis","volume":"39","author":"Liu","year":"2004","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2024.02.002_bib48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/2050640619862721","article-title":"Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: a randomised, crossover clinical trial","volume":"7","author":"Trifan","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial","volume":"12","author":"Lunia","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib50","article-title":"Probiotics for people with hepatic encephalopathy","volume":"2017","author":"Dalal","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","article-title":"Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases","volume":"39","author":"Loguercio","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2024.02.002_bib52","article-title":"Mechanisms of colonization resistance","author":"Fehervari","year":"2021","journal-title":"Nature Research"},{"issue":"5","key":"10.1016\/j.cld.2024.02.002_bib53","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2024.02.002_bib54","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib55","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","article-title":"Promises of microbiome-based therapies","volume":"76","author":"Bajaj","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2024.02.002_bib56","doi-asserted-by":"crossref","first-page":"G824","DOI":"10.1152\/ajpgi.00230.2018","article-title":"Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis","volume":"315","author":"Bajaj","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"475","key":"10.1016\/j.cld.2024.02.002_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7975","article-title":"An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans","volume":"11","author":"Kurtz","year":"2019","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib59","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib60","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1053\/j.gastro.2019.01.033","article-title":"Long-term outcomes after fecal microbiota transplant in cirrhosis","volume":"156","author":"Bajaj","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2024.02.002_bib62","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/hep4.1950","article-title":"Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient","volume":"6","author":"Bloom","year":"2022","journal-title":"Hepatol Commun"},{"issue":"21","key":"10.1016\/j.cld.2024.02.002_bib63","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2024.02.002_bib64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.chom.2022.03.016","article-title":"Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers","volume":"30","author":"Dsouza","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"16","key":"10.1016\/j.cld.2024.02.002_bib65","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jama.2023.4314","article-title":"VE303, a defined bacterial consortium, for prevention of recurrent clostridioides difficile infection: a randomized clinical trial","volume":"329","author":"Louie","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.cld.2024.02.002_bib66","doi-asserted-by":"crossref","first-page":"e1613","DOI":"10.1093\/cid\/ciaa1430","article-title":"RBX7455, a non-frozen, orally administered investigational live biotherapeutic, is safe, effective, and shifts patients\u2019 microbiomes in a phase 1 study for recurrent clostridioides difficile infections","volume":"73","author":"Khanna","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib67","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/hep.24273","article-title":"AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct\u2013ligated rats","volume":"53","author":"Bosoi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.02.002_bib68","first-page":"S84","article-title":"190 AST-120 (spherical carbon adsorbent) in covert hepatic encephalopathy: results of the astute trial","volume":"58","author":"Bajaj","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.02.002_bib70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jsbmb.2015.08.020","article-title":"Modulation of GABAA receptors by neurosteroids. A new concept to improve cognitive and motor alterations in hepatic encephalopathy","volume":"160","author":"Agusti","year":"2016","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2021.03.012","article-title":"A\u00a0pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy","volume":"75","author":"Montagnese","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11011-013-9376-4","article-title":"Acetyl-L-carnitine in hepatic encephalopathy","volume":"28","author":"Malaguarnera","year":"2013","journal-title":"Metab Brain Dis"},{"issue":"4","key":"10.1016\/j.cld.2024.02.002_bib73","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11011-005-7906-4","article-title":"Limited capacity for ammonia removal by brain in chronic liver failure: potential role of nitric oxide","volume":"20","author":"Rose","year":"2005","journal-title":"Metab Brain Dis"},{"issue":"6","key":"10.1016\/j.cld.2024.02.002_bib74","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3109\/00365521.2011.565067","article-title":"Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy","volume":"46","author":"Malaguarnera","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib75","article-title":"Acetyl-L-carnitine for patients with hepatic encephalopathy","volume":"2019","author":"Mart\u00ed-Carvajal","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4\u20135","key":"10.1016\/j.cld.2024.02.002_bib76","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.neuint.2007.05.004","article-title":"The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy","volume":"52","author":"Ahboucha","year":"2008","journal-title":"Neurochem Int"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib77","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/hep.510280212","article-title":"Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study","volume":"28","author":"Barbaro","year":"1998","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2024.02.002_bib78","article-title":"Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy","volume":"2017","author":"Goh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2024.02.002_bib79","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.24412","article-title":"Branched-chain amino acids as pharmacological nutrients in chronic liver disease","volume":"54","author":"Kawaguchi","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2024.02.002_bib80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0928-4346(94)00159-3","article-title":"Clearance rate of plasma branched-chain amino acids correlates significantly with blood ammonia level in patients with liver cirrhosis","volume":"3","author":"Yamato","year":"1995","journal-title":"Int Hepatol Commun"},{"issue":"1","key":"10.1016\/j.cld.2024.02.002_bib81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0168-8278(90)90278-Y","article-title":"Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group","volume":"11","author":"Marchesini","year":"1990","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2024.02.002_bib82","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0016-5085(89)91517-5","article-title":"Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis","volume":"97","author":"Naylor","year":"1989","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2024.02.002_bib83","article-title":"Branched-chain amino acids for people with hepatic encephalopathy","volume":"5","author":"Gluud","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2024.02.002_bib84","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jceh.2022.07.087","article-title":"Intravenous branched chain amino acid infusion is associated with early but ill-sustained recovery of overt hepatic encephalopathy in acute-on-chronic liver failure: a pilot protocol","volume":"12","author":"Mehtani","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2024.02.002_bib85","doi-asserted-by":"crossref","first-page":"e00222","DOI":"10.14309\/ctg.0000000000000222","article-title":"Safety, tolerability, and physiological effects of AXA1665, a novel composition of amino acids, in subjects with Child-Pugh A and B cirrhosis","volume":"11","author":"Chakravarthy","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2024.02.002_bib86","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.mayocp.2015.03.003","article-title":"Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy","volume":"90","author":"Tapper","year":"2015","journal-title":"Mayo Clin Proc"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T05:42:17Z","timestamp":1711518137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326124000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1089326124000138"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2024.02.002","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future Therapies of Hepatic Encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}